Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Which Patients Benefit?
2013; Elsevier BV; Volume: 64; Issue: 3 Linguagem: Inglês
10.1016/j.eururo.2013.06.002
ISSN1873-7560
AutoresGünter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian Stensland, Peter Albers,
Tópico(s)Viral-associated cancers and disorders
ResumoLevel I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
Referência(s)